Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 5/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | GPR4 | P46093 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
| ▸ | NCF1 | P14598 | 1/20 | 0.34 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.34 |
| ▸ | BPTF | Q12830 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16569842 | 0.98 | ADRB1 (0.37) | ADRB1HTR2CHRH1RIPK1USP2 | |
| SCHEMBL16569606 | 0.93 | HRH1 (0.40) | HTR2CHRH1USP2SMN1; SMN2TDP1 | |
| SCHEMBL13285783 | 0.81 | RIPK1 (0.38) | RIPK1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL13002610 | 0.78 | KDM4E (0.47) | RIPK1USP2SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL16578759 | 0.77 | KHK (0.35) | HTR2CRIPK1ALDH1A1 | |
| SCHEMBL17613248 | 0.76 | RIPK1 (0.39) | RIPK1 | |
| SCHEMBL16578753 | 0.76 | GPR4 (0.38) | ADRB1HTR2CHRH1USP2SMN1; SMN2 | |
| SCHEMBL17975504 | 0.75 | CSNK1E (0.34) | RIPK1 | |
| Hydrochloric Acid SCHEMBL26600230 | 0.75 | ALDH1A1 (0.35) | HTR2CRIPK1ALDH1A1 | |
| SCHEMBL26689929 | 0.74 | RIPK1 (0.44) | RIPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4716532-A2 | BICYCLIC HETEROARYL COMPOUNDS | Quantx Biosciences US, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| WO-2024243304-A2 | BICYCLIC HETEROARYL COMPOUNDS | QUANTX BIOSCIENCES US, INC. (US) | 2024-11-28 | — | — | WO | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| EP-3044221-B1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INST OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2018-02-21 | — | — | EP | disclosed |
| EP-3044221-B1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INST OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2018-02-21 | — | — | EP | disclosed |
| US-9611223-B2 | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2017-04-04 | — | — | US | disclosed |
| US-9611223-B2 | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2017-04-04 | — | — | US | disclosed |
| US-9556148-B2 | N-cyanomethylamides as inhibitors of janus kinase | CADILA HEALTHCARE LIMITED (IN) | 2017-01-31 | — | — | US | disclosed |
| EP-3030561-B1 | N-CYANOMETHYLAMIDES AS INHIBITORS OF JANUS KINASE | CADILA HEALTHCARE LTD (IN) | 2017-01-11 | — | — | EP | disclosed |
| US-20160221953-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INSTITUTE OF CANCER RESEARCH ROYAL CANCER HOSPITAL (THE) (GB) | 2016-08-04 | — | — | US | disclosed |
| US-20160221953-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INSTITUTE OF CANCER RESEARCH ROYAL CANCER HOSPITAL (THE) (GB) | 2016-08-04 | — | — | US | disclosed |
| EP-3044221-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | Institute of Cancer Research: Royal Cancer Hospital (The) (GB) | 2016-07-20 | — | — | EP | disclosed |
| US-20160176849-A1 | N-CYANOMETHYLAMIDES AS INHIBITORS OF JANUS KINASE | CADILA HEALTHCARE LIMITED (IN) | 2016-06-23 | — | — | US | disclosed |
| WO-2015036759-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-03-19 | — | — | WO | disclosed |
| WO-2015036759-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176849-A1 | N-CYANOMETHYLAMIDES AS INHIBITORS OF JANUS KINASE | JAK1, JAK3, JAK2 | ADRB1 4130/4885HTR2C 2895/4885HRH1 812/4885 |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | ADRB1 1308/4885HTR2C 4620/4885HRH1 4512/4885 |
| US-20160221953-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | TNKS, TNKS2, PARP1 | ADRB1 2341/4885HTR2C 1067/4885HRH1 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.